Company Filing History:
1 out of 1 
1 out of 4 Years Active: 2015
Title: The Innovative Contributions of Johannes Henricus Matthias Schellens
Introduction
Johannes Henricus Matthias Schellens is an esteemed inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neoplastic diseases. His innovative approach has culminated in the development of a patent that integrates advanced therapeutic methods and compositions.
Latest Patents
Schellens holds a patent for a pharmaceutical composition designed to treat neoplastic diseases. This patent involves the combination of a taxane, specifically docetaxel, with a CYP3A4 inhibitor, such as ritonavir. The patent details various methods of treatment for neoplastic disease using the administration of both a taxane and the CYP3A4 inhibitor, either separately or simultaneously. Additionally, it describes solid pharmaceutical taxane compositions for oral administration, which include a substantially amorphous taxane, a carrier, and a surfactant. The comprehensive nature of this patent reflects Schellens' innovative spirit in tackling complex medical challenges.
Career Highlights
Throughout his career, Johannes Henricus Matthias Schellens has been affiliated with notable organizations, such as Slotervaart Participaties Bv and Stichting Het Nederlands Kanker Instituut. His work in these institutions has strengthened the potential of his innovative breakthroughs in pharmaceutical sciences.
Collaborations
Schellens has collaborated with several distinguished professionals in the field, including Jacob Hendrik Beijnen and Johannes Jan Moes. These collaborations have enabled him to broaden his research and enhance the efficacy of his innovations in cancer treatment.
Conclusion
Johannes Henricus Matthias Schellens exemplifies the role of an inventor in the ever-evolving landscape of medical research. His patent for innovative pharmaceutical compositions highlights the importance of combining various treatment methods to effectively address neoplastic diseases. Through his collaborations and career advancements, Schellens continues to pave the way for future innovations in the pharmaceutical industry.